MedPath

Investigation of Administration of MCT/ω-3 Fatty Acids is Towards Anti-inflammatory Related Fatty Acid Profile in Preterm Neonates.

Not Applicable
Completed
Conditions
Premature Birth
Interventions
Dietary Supplement: soybean oil-based IVFE
Dietary Supplement: MCT/ω-3 fatty acids
Registration Number
NCT04586608
Lead Sponsor
Iaso Maternity Hospital, Athens, Greece
Brief Summary

Intravenous administration of pure soybean oil emulsions high in linoleic acid may lead to inflammation and lipid peroxidation in preterm neonates. The aim of the present study was to investigate the effects of a medium-chain triglyceride (MCT)/n-3 polyunsaturated fatty acid (PUFA)-enriched intravenous fat emulsion (IVFE) on plasma fatty acid (FA) profile in preterm neonates. Methods: In this double-blind randomized study, 92 preterm neonates (gestational age \<32 weeks, birth weight \<1500g) were assigned to receive either MCT/n-3 PUFA-enriched IVFE (Intervention Group) or soybean oil-based IVFE (Control Group). Neonates' parents gave their informed written consent for inclusion in the study. Levels of FAs were measured at baseline (day 0) and day 15 of parenteral nutrition with gas-chromatography mass-spectrometry.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
92
Inclusion Criteria

Preterm neonates with gestational age <32 weeks

  • birth weight <1500 g
  • admitted to a tertiary neonatal intensive care unit within 12 hours after birth
Exclusion Criteria
  • anticipated needs for parenteral nutrition (PN) at ˃70% of total daily energy for <10 days evidence of intrauterine infection,
  • perinatal asphyxia
  • major congenital anomalies
  • refusal of parental consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
soybean oil-based IVFEsoybean oil-based IVFEsoybean oil-based IVFE
active comparatorMCT/ω-3 fatty acids-
Primary Outcome Measures
NameTimeMethod
Alterations on Metabolic Fatty Acid Profile of the Premature Neonatestwo years

the detection of clinically significant differences in plasma n-3 PUFAs, n-6 PUFAs and EPA in the MCT/ω-3 PUFA-enriched IVFE group compared to the SO-IVFE group post intervention.

the detection of clinically significant differences in plasma n-3 PUFAs, n-6 PUFAs and EPA in the MCT/ω-3 PUFA-enriched IVFE group compared to the SO-IVFE group post intervention.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Panos Papandreou

🇬🇷

Athens, Greece

© Copyright 2025. All Rights Reserved by MedPath